Kairos Pharma Ltd. (NYSE American: KAPA), a Los Angeles-based oncology therapeutics company, announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis revealed a statistically significant difference in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to two months for those receiving apalutamide alone (P=0.0008). This dramatic difference suggests that ENV-105 may substantially delay disease progression in a patient population with limited treatment options.
In response to these encouraging results, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression. Patients who experience a prostate-specific antigen (PSA) increase following upfront treatment with an androgen signaling inhibitor will now be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. The company stated that this change is intended to expand the eligible patient population and facilitate enrollment, with completion of the Phase 2 trial targeted in or before the fourth quarter of 2027. For investors and patients, this modification could lead to faster trial completion and potentially accelerate the path to regulatory approval.
ENV-105 is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The positive interim data not only validate this approach but also highlight the potential of ENV-105 to become a cornerstone in combination regimens for prostate cancer.
The implications of this announcement extend beyond Kairos Pharma. Prostate cancer remains a leading cause of cancer death among men, and metastatic castration-resistant prostate cancer is particularly challenging to treat. A therapy that can significantly extend progression-free survival could transform the treatment landscape, offering new hope to patients and potentially reducing healthcare costs associated with disease progression. For the biotechnology industry, this data underscores the value of targeting resistance mechanisms and may spur further investment in similar approaches.
For more details on this announcement, the full press release is available at https://ibn.fm/EDpxx. Investors and industry observers can find ongoing updates on Kairos Pharma in the company’s newsroom at https://ibn.fm/KAPA. This news was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and offers services such as editorial syndication to 5,000+ outlets and social media distribution. For more information about BioMedWire, visit https://www.BioMedWire.com.
